Injectsense

What Injectsense does

Injectsense is a private medical device company founded in 2014 and headquartered in Emeryville, California, developing an ultra-miniature implantable sensor platform for continuous in-vivo physiological monitoring. Its core product, the IOP-Connect sensor, is a fully implantable wireless intraocular pressure sensor under 2 cubic millimeters in size that self-anchors in the pars plana via an in-office injection procedure similar to standard intravitreal injections and measures absolute IOP at programmable intervals from once per hour to once per millisecond. The device is powered by a solid-state rechargeable microbattery developed by sister company Injectpower (backed by 40+ CEA/LETI patents), recharged wirelessly through smart glasses via near-field inductive coupling, and transmits data to a cloud-based analysis platform that applies anomaly detection and physician-configured alerts. The platform is designed to address continuous 24/7 glaucoma management, with stated future applications in intracranial and cardiovascular pressure monitoring, and the company cites an addressable market of 4 million US patients and 14 million European patients.

The company employs 11–50 people across Emeryville (semiconductor engineering), Minneapolis (medical systems and software), and a forthcoming Injectpower manufacturing facility in Grenoble, France. Its business model is pre-commercial: the IOP-Connect is investigational only, and current revenue is limited to development services provided to a single major non-ophthalmic device company for sensor integration into partner products. The regulatory and clinical pathway is anchored by the FDA Breakthrough Device Designation (September 2020), a $1.7M NIH SBIR grant (March 2022) that funded Johns Hopkins animal testing, an approved 20-patient first-in-human study in Chile (May 2024), and the first human implantation completed in August 2024. Capital structure to date includes a 2016 seed round, an April 2019 Series B, the 2022 SBIR grant, the November 2023 combined $9.4M funding for Injectsense and Injectpower (led by IDEC Group with Bpifrance), and a Series C round expected in 2024 to support commercialization. Future go-to-market is planned as enterprise field sales of the implant to ophthalmologists and glaucoma specialists at eye clinics and hospitals, with a manufacturing supply chain already established for hundreds of thousands of devices per month using wafer-scale semiconductor production.

Name

Injectsense

Legal name

Injectsense Inc.

Website

https://injectsense.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Injectsense is a private medical device company developing the IOP-Connect, an ultra-miniature implantable wireless sensor for continuous 24/7 intraocular pressure monitoring in glaucoma patients, powered by a solid-state microbattery from sister company Injectpower. The investigational device is sold under development agreements today and targets ophthalmologists globally upon FDA approval.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Ophthalmic Goods (3851)

akta.pro primary industry

Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI)

akta.pro secondary industry

Sensor Fusion, Interface ICs & Modules (AFE/Readout/Packaging/Calibration) (HDAHALAO)

Keywords

• Implantable pressure sensors
• Intraocular pressure monitoring
• Glaucoma management devices
• Medical implantables
• Wireless biosensors

Headquarters

HQ city

Emeryville

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Development Revenue: Injectsense currently has development revenue from a major non-ophthalmic device company. This represents revenue from sensor development services and prototypes for potential integration into partner products.
2. Future Hardware Sales: Once FDA market authorization is obtained, the company plans to commercialize its implantable sensor platform. Revenue will come from selling devices to eye clinics and hospitals for glaucoma management. The supply chain can produce hundreds of thousands of devices per month.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Injectsense develops and manufactures the IOP-Connect, an ultra-miniature (less than 2 cubic millimeters, smaller than a grain of rice) fully implantable wireless intraocular pressure sensor that is injected in-office into the eye to provide continuous 24/7 IOP monitoring for glaucoma patients over decades. The platform pairs the sensor with an Injectpower solid-state microbattery and smart-glass wearable that wirelessly recharges the implant weekly and uploads pressure waveform data to a cloud-based analysis software used by ophthalmologists.

Product overview

Injectsense is a sensor-enabled digital health company offering an ultra-miniature implantable sensor platform for continuous physiological monitoring. The core product is the IOP-Connect sensor, an implantable wireless intraocular pressure sensor smaller than a grain of rice that provides continuous 24/7 monitoring over decades. The platform integrates the Injectpower solid-state microbattery as a power source and uses proprietary smart glasses for weekly wireless recharging and data upload. The system transmits data to a secure cloud platform with analysis software that provides physicians with continuous IOP waveforms and anomaly alerts. Injectsense is developing additional sensors for intracranial pressure (ICP) and cardiovascular pressure monitoring applications. All devices are investigational and not commercially available.

Differentiator

Problem solved

Functional benefit

Brands

• IOP-Connect: Ultra-miniature, fully implantable wireless intraocular pressure sensor platform for continuous 24/7 IOP monitoring in glaucoma patients.
• Injectpower

Products and services

• IOP-Connect Intraocular Pressure Sensor An ultraminiature, fully implantable wireless intraocular pressure sensor (less than 2 cubic millimeters) that self-anchors in the pars plana via an in-office injection and continuously measures absolute IOP over decades for glaucoma management. It is intended for use by ophthalmologists treating glaucoma patients.
• Smart Glasses Wearable Receiver
• IOP-Connect Data Analysis Software
• Injectpower Solid-State Microbattery

Quantifiable outcome

• Measured drift of only 0.006 mmHg/month in 3-month stability testing with long-term accuracy target of +/- 1 mmHg at system level
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered key, supporting and core.

• Centro de la Vision ClinickeyStrategic or Co-development Partner · 6 May 2024Clinical study partner in Santiago, Chile led by Dr. Juan Jose Mura. Ethics committee approved 20-patient first-in-human study to confirm safety and effectiveness of IOP-Connect sensor. First implantation completed August 2024.
• CadencesupportingTechnology or IntegrationElectronic design automation (EDA) partner providing design tools for semiconductor chip design and verification of Injectsense's ASIC and MEMS components.
• AnsyssupportingTechnology or IntegrationSimulation software partner providing multiphysics simulation tools for sensor design, thermal analysis, and reliability engineering.
• NAMSAsupportingImplementation/ SI/ Consulting PartnerMedical device consulting and testing partner providing regulatory consulting, biocompatibility testing, and quality management system support.
• InjectpowercoreStrategic or Co-development PartnerSister company and strategic partner developing ultra-miniature solid-state microbatteries for medical applications. Injectpower secured €6.5M funding to build proprietary 200mm MEMS fabrication facility in Grenoble, France. The battery technology is key to enabling autonomous continuous sensing over decades.
• Johns Hopkins Wilmer Eye InstitutekeyStrategic or Co-development PartnerAcademic medical center partner conducting animal testing of Injectsense sensors under guidance of Dr. Thomas Johnson III. Completed 9-month animal study with no adverse events, establishing safety baseline for human studies.
• CEA/LETIsupportingTechnology or IntegrationFrench research institute providing technology development support for Injectpower's solid-state microbattery technology. Over 20 years of technology development and 40+ patents licensed to Injectpower.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Implandata Ophthalmic Products: German developer of the Eyemate system, a CE-marked implantable suprachoroidal IOP sensor for continuous glaucoma monitoring. The most direct functional peer to Injectsense's IOP-Connect, competing on the same paradigm of in-eye continuous pressure sensing for ophthalmologists.
• Sensimed AG: Swiss developer of the Triggerfish, a soft contact lens-based continuous IOP sensor worn for 24-hour monitoring periods. Closest historical competitor in continuous IOP monitoring and the only category analog with actual commercial deployment experience.

Others

• Injectpower: Sister company developing the solid-state lithium microbattery that powers Injectsense's sensor platform. Strategic ecosystem participant and supplier rather than a competitor, but commercial success of Injectsense is tightly coupled to Injectpower's manufacturing scale-up in Grenoble.

Broad incumbents

• iCare Finland Oy: Established manufacturer of rebound tonometers widely used in glaucoma assessment. Represents the incumbent episodic IOP measurement standard that Injectsense is positioned to disrupt, and a likely channel/adoption comparator once IOP-Connect reaches market.
• Reichert Technologies: Long-standing US ophthalmic diagnostic device maker (part of AMETEK) producing tonometers, refractors, and lens analyzers. Broad incumbent in clinical ophthalmic measurement whose installed base and physician relationships frame the competitive context for any new glaucoma diagnostic.
• Heidelberg Engineering: German manufacturer of ophthalmic imaging and diagnostic systems (OCT, confocal microscopy) used in glaucoma and retinal disease management. Broad incumbent whose physician relationships and clinical workflow integration set the bar for Injectsense's data-analytics platform play.
• Carl Zeiss Meditec: Global ophthalmic device and diagnostics platform spanning surgical microscopes, OCT, and laser systems. Broad incumbent across the glaucoma care continuum whose scale and distribution would represent a potential strategic acquirer or channel partner for Injectsense.
• Alcon: Global leader in ophthalmic surgery, vision care, and pharmaceuticals. Broad incumbent with deep ophthalmologist relationships and a glaucoma surgical portfolio; relevant as both a competitive threat and the most likely strategic acquirer of a successful continuous IOP monitoring platform.
• BVI Medical: Global ophthalmic surgical device company covering cataract, vitreoretinal, and glaucoma surgical instrumentation. Broad incumbent whose intravitreal injection and surgical delivery expertise overlaps with Injectsense's physician channel and self-anchoring in-office delivery model.

Emerging players

• Glaukos Corporation: US public company pioneering minimally invasive glaucoma surgery (MIGS) devices such as iStent. Operates in the same glaucoma-treatment workflow as Injectsense but addresses surgical intervention rather than diagnostics, making it a complementary emerging player in the same physician call point.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/injectsense
• Instagraminstagram.com/injectsense

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Injectsense